Results 61 to 70 of about 104,641 (308)
Amphotericin B formulation trends over time. Annual percentage of patients receiving lipid formulation amphotericin B (LF AmpB) or deoxycholate amphotericin B (AmpBd) for initial therapy (N = 132).
Nada El Husseini (310362) +8 more
core +1 more source
Multi‐Targeting Carnosic Acid Kills Drug‐Resistant Helicobacter pylori With Narrow‐Spectrum Activity
Carnosic acid selectively eradicates drug‐resistant Helicobacter pylori through a multi‐targeted mechanism involving urease inhibition, membrane disruption, and biofilm eradication. It exhibits no detectable resistance, potent in vivo efficacy, and minimal impact on gut microbiota, positioning it as a promising narrow‐spectrum lead compound against ...
Yuefan Bai +7 more
wiley +1 more source
Liposomal amphotericin B as a treatment for human leishmaniasis
INTRODUCTION: Leishmaniasis is a parasitic disease transmitted by phlebotomine sandflies. Between 700,000 and 1.2 million cases of cutaneous leishmaniasis and between 200,000 and 400,000 cases of visceral leishmaniasis (VL), which is fatal if left ...
Potet, Julien +8 more
core +1 more source
UBE2O targets CDKL1 for the degradation to upregulate PD‐L1 expression and promotes resistance to radioimmunotherapy in lung cancer, supporting the potential of targeting UBE2O as a promising therapeutic strategy. ABSTRACT Resistance to radioimmunotherapy is one of the primary causes of treatment failure in lung cancer patients; however, the underlying
Huichan Xue +6 more
wiley +1 more source
In Brazil, meglumine antimoniate is the first drug of choice for mucosal leishmaniasis treatment followed by amphotericin B and pentamidine isethionate.
Benivaldo Ramos Ferreira Terceiro +8 more
doaj +1 more source
Disseminated histoplasmosis is the main AIDS-defining infection of French Guiana. We aim to describe our therapeutic experience for 349 patients with disseminated histoplasmosis between 1 January 1981 and 10 January 2014 in French Guiana.
Mathieu Nacher +11 more
doaj +1 more source
Efficacy of aerosolized liposomal amphotericin B against murine invasive pulmonary mucormycosis
Invasive pulmonary mucormycosis is a life-threatening fungal infection encountered in immunocompromised patients. An intravenous high-dose lipid formulation of amphotericin B, such as liposomal amphotericin B (L-AMB), is the recommended treatment.
Kakeya, Hiroshi +17 more
core +1 more source
Background and Objectives: Amphotericin B is a broad-spectrum antifungal agent commonly used to treat Candida haemulonii infection. C. haemulonii was isolated from patients reported to be intrinsically resistant to amphotericin B, encoded by the ERG2 ...
Rifdah Hanifah +2 more
doaj +1 more source
ABSTRACT Introduction Chronic rhinosinusitis (CRS) is an inflammatory disease with many different contributing factors, including bacterial infection. CRS patients are typically managed with medical therapies; however, these treatments frequently fail, leaving surgery as the only viable option.
Sintayehu Ambachew +8 more
wiley +1 more source
Biomimetic electrospun scaffold incorporating GDF‐7‐loaded mesoporous silica nanoparticles, combined with mechanical stimulation and physiological oxygen tension, guides tenogenic differentiation of mesenchymal stromal cell and tendon progenitor stem cell. This integrated approach enhances cell proliferation, matrix deposition, and tendon‐specific gene
Vera Citro +3 more
wiley +1 more source

